Posted by Michael Wonder on 24 May 2021
Akeso's penpulimab monoclonal antibody submitted BLA in the United States
24 May 2021 - First Chinese PD-1 drug being BLA reviewed by the FDA under real-time oncology review.
Akeso announced today that penpulimab (AK105), a PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical, has submitted a biologics license application to the United States FDA for third-line treatment of metastatic nasopharyngeal carcinoma.
